February, 2017

How Oncotarget is improving the Quality of Scientific Research

Oncotarget is a medical journal that publishes papers on oncology and is released weekly. The journal is open-access. It is free for all and anyone is allowed to view it. It is also a peer-reviewed journal which means that research must be reviewed and counter-checked by other members of the scientific community before Oncotarget publishes it.

The editors-in-chief at Oncotarget are Mikhail Blagosklonny and Andrei Gudkov, both of whom work at the Roswell Park Cancer Institute in New York. Blagosklonny is a professor of oncology at the Institute. He is an expert in fields such as cancer and aging. Gudkov is a senior vice president for basic research at the Institute and a professor of cell stress biology.

Research Gate has it that its editorial board is made up of distinguished scientists and researchers including some who have won Lasker Awards. They are the reason why Oncotarget is where it is today because they ensure that the quality is very high.

Oncotarget is indexed by BIOSIS Previews, PubMed, and Scopus where they have been ranked Q1 for five years in a row. The journal was started in 2010 and has become the top journal covering research on oncology. Oncotarget is published by Impact Journals and archives of previous issues can be found on the journal’s site.

The journal has turned out to be successful. It has maintained an impact factor of 5.00 since its founding. The editors saw it best to include other sections that are closely related with oncology including cardiology, aging, neuroscience, and immunology even though it started by focusing on one field only.

According to Dove Press, Oncotarget has made it easier for scientific research to spread faster because it is published online instead of being printed and distributed. Discoveries are shared quickly, and this is a huge advantage for the scientists and researchers who would like many people to know about their scientific breakthroughs.

Oncotarget has facilitated the collaboration of scientists from different fields which has led to significant discoveries. Oncotarget has published some of the most important papers of recent years because of the relationship that it maintains with the researchers.

Capital Group Engages More People through Advertisement, Research On Active Management And By Putting More Emphasis On Product Sales

Mr. Armor, who chairs the Capital’s administration council in his current duty, has been a key assistant to Mr. Rothenberg, and besides being part of the administrators championing in-house investigation that was designed to portray the long-lasting advantages of specific types of active fund management. He additionally assumed duty in Capital’s choice, over late years, to lift some of the privacy around its operations and ensure he engaged more with the media. In the meantime, the organization has honed its business operations and delighted in the products of enhanced long haul execution records for key assets, including at its notable suite of American Funds common assets.

Later, the Capital mutual funds shared assets in new trades compared with the other group, bar list tracker index Vanguard, as per Lipper information. Vanguard stood out with $127bn in inflows, with Capital drawing $17bn. “Individuals shouldn’t remain for benchmark returns since they were options out there that are greatly improved,” Mr. Armor said before in a meeting with the Financial Times. Dynamic directors can do well in the market as time goes on. That is as long as they ensure expenses are affordable and cannot churn their portfolios, and in the event that they have a background marked by portfolio chiefs putting resources into their own particular support, Capital’s in-house research found.

Timothy D. Armour is Capital Group Companies’ chairman, Capital Research and Management Company, Inc. principal executive officer and chairman, (which is part of the Capital Group) and Capital Group Companies Management Committee chairman besides being an equity portfolio manager. Tim has 32 years of experience in investigation, all with Capital Group. Prior in his profession, as an equity speculation expert at Capital, he covered worldwide media communications and U.S. benefit organizations. Tim started his vocation at Capital as a member in The Associates Program. He has a bachelor’s degree from Middlebury College where he studied economics. Tim is situated in Los Angeles.

Mr. Armour served for a long time as the Chief Director and later as the official VP of the JASON Foundation for Education, a charitable association focused on enhancing science and math inspiration and performance among middle school learners. Mr. Armour prior profession incorporates start-up and official duties in business in addition the senior outer relations & fundraising officer at Harvard Business School, and alumni and fundraising relations at Amherst College.